Braun-Bostich & Associates’s Johnson & Johnson JNJ Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.62M Sell
6,374
-129
-2% -$30.1K 0.9% 32
2026
Q1
$1.59M Sell
6,503
-472
-7% -$110K 1% 32
2025
Q4
$1.44M Sell
6,975
-602
-8% -$119K 0.89% 32
2025
Q3
$1.4M Sell
7,577
-2
-0% -$343 0.89% 32
2025
Q2
$1.16M Buy
7,579
+71
+0.9% +$10.9K 0.79% 36
2025
Q1
$1.25M Buy
7,508
+25
+0.3% +$3.91K 0.92% 32
2024
Q4
$1.08M Sell
7,483
-294
-4% -$45.6K 0.78% 34
2024
Q3
$1.26M Buy
7,777
+483
+7% +$77K 0.88% 30
2024
Q2
$1.07M Buy
7,294
+630
+9% +$93.7K 0.79% 33
2024
Q1
$1.05M Buy
6,664
+317
+5% +$50.5K 0.88% 31
2023
Q4
$995K Buy
6,347
+4,861
+327% +$745K 0.9% 25
2023
Q3
$231K Sell
1,486
-3,309
-69% -$546K 0.43% 46
2023
Q2
$794K Buy
4,795
+328
+7% +$52.9K 1.7% 19
2023
Q1
$692K Buy
4,467
+477
+12% +$77K 1.64% 23
2022
Q4
$705K Buy
3,990
+172
+5% +$29.7K 2.03% 20
2022
Q3
$624K Buy
3,818
+80
+2% +$13.5K 1.91% 23
2022
Q2
$664K Buy
3,738
+113
+3% +$20.1K 1.73% 25
2022
Q1
$642K Buy
3,625
+2,276
+169% +$387K 1.38% 23
2021
Q4
$226K Sell
1,349
-1,864
-58% -$305K 0.05% 99
2021
Q3
$519K Hold
3,213
0.98% 29
2021
Q2
$529K Sell
3,213
-70
-2% -$11.6K 0.96% 27
2021
Q1
$540K Sell
3,283
-35
-1% -$5.66K 1.04% 26
2020
Q4
$522K Sell
3,318
-3,617
-52% -$534K 1.05% 29
2020
Q3
$1.03M Sell
6,935
-3,480
-33% -$515K 1.03% 20
2020
Q2
$1.47M Buy
10,415
+243
+2% +$35.4K 1.43% 12
2020
Q1
$1.31M Sell
10,172
-377
-4% -$53.5K 1.67% 10
2019
Q4
$1.54M Sell
10,549
-112
-1% -$15.2K 1.52% 13
2019
Q3
$1.38M Buy
10,661
+387
+4% +$51K 1.6% 12
2019
Q2
$1.43M Sell
10,274
-41
-0.4% -$5.67K 1.5% 12
2019
Q1
$1.44M Sell
10,315
-1,869
-15% -$250K 1.5% 11
2018
Q4
$1.57M Sell
12,184
-3,575
-23% -$499K 1.67% 14
2018
Q3
$2.18M Buy
15,759
+22
+0.1% +$2.92K 2.1% 10
2018
Q2
$1.91M Buy
15,737
+4,073
+35% +$508K 1.91% 9
2018
Q1
$1.5M Sell
11,664
-1,397
-11% -$189K 1.29% 22
2017
Q4
$1.82M Buy
+13,061
New +$1.82M 1.55% 16

Other funds holding JNJ

Braun-Bostich & Associates's JNJ Position: Q2 2026 in Review

Braun-Bostich & Associates reduced its Johnson & Johnson (JNJ) stake by 2% in Q2 2026, selling an estimated $30.1K and leaving 6,374 shares worth $1.62M. The position accounts for 0.9% of the portfolio, ranked #32.

Braun-Bostich & Associates first reported a position in JNJ in Q4 2017 and has held it in 35 quarters since. The position peaked at $2.18M in Q3 2018. 1,657 funds tracked by Wall St. Rank hold JNJ as of Q2 2026.

  • Braun-Bostich & Associates held 6,374 shares of Johnson & Johnson worth $1.62M as of Q2 2026.
  • Braun-Bostich & Associates sold 129 Johnson & Johnson shares in Q2 2026, an estimated $30.1K.
  • Johnson & Johnson made up 0.9% of Braun-Bostich & Associates's portfolio in Q2 2026, its #32 holding.
  • Braun-Bostich & Associates first reported a position in Johnson & Johnson in Q4 2017 and has held it in 35 quarters since.
  • Braun-Bostich & Associates's Johnson & Johnson position peaked at $2.18M in Q3 2018.
  • 1,657 funds tracked by Wall St. Rank held Johnson & Johnson as of Q2 2026.

Based on Braun-Bostich & Associates's 13F filing for Q2 2026, filed 24 Jul 2026.